Abstract
Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.
Keywords: Therapy of MDR-TB, XDR-TB, Mycobacterium tuberculosis, thioridazine, efflux pumps
Current Drug Targets
Title: Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps
Volume: 9 Issue: 9
Author(s): L. Amaral, M. Martins, M. Viveiros, J. Molnar and J. E. Kristiansen
Affiliation:
Keywords: Therapy of MDR-TB, XDR-TB, Mycobacterium tuberculosis, thioridazine, efflux pumps
Abstract: Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.
Export Options
About this article
Cite this article as:
Amaral L., Martins M., Viveiros M., Molnar J. and Kristiansen E. J., Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps, Current Drug Targets 2008; 9 (9) . https://dx.doi.org/10.2174/138945008785747798
DOI https://dx.doi.org/10.2174/138945008785747798 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report
Current Drug Safety Microwave Induced One Pot Ugi Multicomponent Reaction of Fluoroquino Lone Scaffolds: Their Biological Evaluation
Current Green Chemistry Patent Selections
Recent Patents on Anti-Infective Drug Discovery Virtual Screening Against M. tuberculosis 7,8-Diaminopelargonic Acid Synthase (MtbBioA) and In Silico Toxicity Evaluation of Top Hits
Current Enzyme Inhibition Type II NADH:Menaquinone Oxidoreductase of Mycobacterium tuberculosis
Infectious Disorders - Drug Targets A Review of Molecular Modelling Studies of Dihydrofolate Reductase Inhibitors Against Opportunistic Microorganisms and Comprehensive Evaluation of New Models
Current Pharmaceutical Design Recent Patents for the Treatment of Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis
Recent Patents on Anti-Infective Drug Discovery Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Study of the Scientific Production on Leishmaniasis in Latin America
Recent Patents on Anti-Infective Drug Discovery Role of Moving Average Analysis for Development of Multi-Target (Q)SAR Models
Mini-Reviews in Medicinal Chemistry Structural and Functional Properties of NAD Kinase, a Key Enzyme in NADP Biosynthesis
Mini-Reviews in Medicinal Chemistry Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Trends in Enzyme Inhibition and Activation in Drug Design - Part II
Current Topics in Medicinal Chemistry The Impact of Proteomic Advances on Bacterial Gene Annotation
Current Proteomics Drug Resistance in Tuberculosis: How to Counter The Menace?
Current Pharmaceutical Biotechnology Understanding the Structure, Activity and Inhibition of Chorismate Synthase from Mycobacterium tuberculosis
Current Medicinal Chemistry